FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Reported 48-week US Phase 2 results for its MASH candidate DD01 and has licensed its oral peptide platform abroad. Also seen: Discovery · preclinical

  • Disclosed 48-week liver biopsy results for DD01 at EASL 2026. Source

Roles often seen at this stageClinical & PV · Research & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

D&D Pharmatech

A developer of peptide drugs for metabolic disease and fatty-liver disease that owns the ORALINK oral peptide platform.

DD01

Phase 2

A GLP-1/glucagon dual agonist; in the 48-week US Phase 2 liver biopsy analysis, MASH resolution without worsening fibrosis was 62.5% on DD01 versus 5.3% on placebo.

ORALINK

Technology platform

A long-acting oral peptide platform; first licensed to Metsera in April 2023 (about KRW 550 billion) with the scope expanded in March 2024.

Completion reported

Completed 48-week dosing of all enrolled patients in the US Phase 2 trial of DD01.

Completion reported

Presented 48-week liver biopsy results of the DD01 Phase 2 trial at EASL Congress 2026.

Official role guide

D&D Pharmatech careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 디앤디파마텍 MASH 치료제 DD01, 미국 임상 2상 전체 환자 48주 투약 완료 ↗디앤디파마텍 · Published 2026-01-02 · Sources checked 2026-11-18 · Original unavailable
  2. 화이자, '멧세라' 인수... 디앤디파마텍 기술이전 파이프라인도 주목 ↗히트뉴스 · Published 2025-09-23 · Sources checked 2026-11-18 · Original unavailable
  3. 디앤디파마텍 "DD01, 美2상 48주 간생검 '지방간염 소실·섬유화 개선'"(상보) ↗더바이오 · Published 2026-05-27 · Sources checked 2026-11-18 · Original unavailable
  4. 디앤디파마텍 채용 안내 ↗디앤디파마텍 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable